Key facts
- Swan Neck Bio’s last known valuation is $10.7M (Oct 2025).
- It has raised $4.0M; the latest was Early Stage VC ($3.4M) in Oct 2025.
- Notable investors include Angular Ventures, Future Five.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Swan Neck Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Swan Neck Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Swan Neck Bio
Provider of biotechnology services intended to progress the bio services needed by a growing population. The company offers services designed to improve biomanufacturing outcomes at the pilot scale and also improve microorganism robustness, increasing yields, enhancing efficiency, and accelerating the time-to-market, enabling food and biotech companies to validate the commercial potential of the microorganism.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2023
- Employees
- 10
- Website
- swanneck.bio/
- Ownership
- Privately Held (backing)
Swan Neck Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Swan Neck Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Swan Neck Bio in its N-PORT filings yet. We sweep new filings monthly.